Levetiracetam (Epilepsy) - Medication and Pregnancy KB

Levetiracetam (Epilepsy)

Amniotic fluid problems (polyhydramnios and/or oligohydramnios)

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S12502 R47873	Mari (Levetiracetam), 2022	Oligohydramnios/polyhydramnios	throughout pregnancy	retrospective cohort	exposed to other treatment, sick	Adjustment: No	0.64 [0.01;34.59] ^C	0/17 0/11	0	17		ref
S8083 R24697	Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020	Amniotic fluid problems (polyhydramnios/oligohydramnios)	throughout pregnancy	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.68 [0.01;39.07] ^C excluded (control group)	0/10 0/7	0	10		ref
S8081 R24677	Aydin (Levetiracetam) (Controls unexposed, sick), 2020	Amniotic fluid problems (polyhydramnios/oligohydramnios)	throughout pregnancy	retrospective cohort	unexposed, sick	Adjustment: No	2.26 [0.04;122.79] ^C	0/10 0/22	0	10		ref
					Total	2 studies	1.20 [0.07;20.23]		0	27
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Levetiracetam; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8083